The traditional venture capital approach to biotech investing is facing significant disruption, according to a new analysis. For decades, venture capitalists have operated with a consistent strategy for funding drug development companies. That established formula is now under pressure as the industry landscape shifts.
The report describes a 'tried-and-true recipe' that VCs have relied on to generate returns in the high-risk biotech sector. This model typically involved specific stages of funding tied to clinical trial milestones. The predictability of this approach is now being challenged by evolving scientific, regulatory, and economic conditions.